Raptor Pharma (RPTP) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Raptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate Update
February 25, 2016 4:07 PM EST2015 Global Net Revenue for PROCYSBI® of $94.2 Million Reported
2016 Global Net Revenue Guidance of $115 to $125 Million
2016 Anticipated PROCYSBI Growth of 25%-30% Year-Over Year
Company to Host Conference Call and Webcast Today at 4:30 p.m. ET
NOVATO, Calif., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ: RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,... More
